Clinical Trial

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2024 (before its estimated April 26, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the safety and efficacy of allogeneic γδ T cells combined with targeted therapy and PD-1 monoclonal antibody in patients with hepatocellular carcinoma resistant to PD-1 monoclonal antibody. Hepatocellular Carcinoma
Trial Details
NCT Number NCT06364800
Lead Sponsor Beijing 302 Hospital
Collaborators: Chinese Academy of Medical Sciences, Beijing GD Initiative Cell Therapy Technology Co., Ltd.
Conditions Hepatocellular Carcinoma
Enrollment 18 participants
Start Date 2024-04-26
Primary Completion 2026-04-26 (estimated)
Study Completion 2026-09-26 (estimated)
Updated on ClinicalTrials.gov 2024-04-15